Red blood cell (RBC) alloimmunization can occur because of exposure to various sensitizing factors and poses a constant threat in transfusion. Assisted reproductive technology (ART) involves manipulation of sperm, ova, or embryos with the goal of producing a pregnancy. We present an interesting case of ART-induced maternal alloimmunization (AIMA) due to anti-c in a woman carrying a twin pregnancy. A 35-year-old primigravida, whose blood sample typed as group B, D+ and showed anti-c in her plasma, delivered twins by cesarean section. The spouse's blood group was also B, D+. The blood groups of twins I and II were confirmed to be B, D+ and AB, D+, respectively. The RBCs of twin I were c+, but those of twin II and the spouse were c-. On enquiry, history of ART with donor sperm insemination was noted. Because there were no previous sensitizations, antigenic inheritance from the sperm donor to twin I could be the possible sensitizing factor for maternal alloimmunization. To the best of our knowledge, this case is the first report of ART-induced maternal RBC alloimmunization in the literature. History of ART exposures should be documented, and appropriate RBC phenotyping of the parent as well as potential ART donors will help in timely detection or prevention of hemolytic disease of the fetus and newborn or other AIMA-related complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2478/immunohematology-2024-020 | DOI Listing |
Immunohematology
December 2024
Transfusion Medicine, Dr. Rela Institute & Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamilnadu, India.
Red blood cell (RBC) alloimmunization can occur because of exposure to various sensitizing factors and poses a constant threat in transfusion. Assisted reproductive technology (ART) involves manipulation of sperm, ova, or embryos with the goal of producing a pregnancy. We present an interesting case of ART-induced maternal alloimmunization (AIMA) due to anti-c in a woman carrying a twin pregnancy.
View Article and Find Full Text PDFBMC Pregnancy Childbirth
December 2024
Immunology LATAM, Janssen, Mendoza, Buenos Aires, CP (1428), 1259, Argentina.
Background: Hemolytic disease of the fetus and newborn (HDFN) is a condition due to maternal blood group antibodies targeting antigens in fetal red blood cells, with significant prenatal/perinatal morbidity and mortality. Severe HDFN cases are often associated with alloimmunization against Rhesus D (RhD) or Kell antigens. Information about HDFN epidemiology and treatment in Latin American countries is limited.
View Article and Find Full Text PDFCureus
November 2024
Pathology and Laboratory Medicine, University of South Alabama College of Medicine, Mobile, USA.
The anti-M antibody is a cold, naturally occurring immunoglobulin M (IgM) antibody that is generally considered clinically insignificant and often overlooked in transfusion practices and assessments of patients at risk for hemolytic disease of the fetus and newborn (HDFN). However, the presence of an IgG component in this case renders the antibody clinically significant, underscoring the necessity for proper serologic testing during prenatal evaluations. We present a case involving an anti-M antibody with an IgG component to highlight the critical importance of thorough serologic testing during prenatal testing.
View Article and Find Full Text PDFVox Sang
December 2024
Clinical Laboratory Advise, Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands.
Background And Objectives: To test the performance of a new droplet digital polymerase chain reaction (ddPCR) non-invasive foetal blood group and platelet antigen genotyping assay in the setting of a Dutch reference laboratory for foetal blood group and platelet antigen genotyping. Our population comprised 229 consecutive alloimmunized pregnant women who presented between April 2022 and March 2023 with 250 requests for non-invasive foetal RHD, RHE, RHc, RHC, K1, HPA-1a or HPA-5b blood group and platelet antigen genotyping.
Materials And Methods: Samples were genotyped for blood group and platelet antigen alleles along with methylated RASSF1a (mRASSF1a) and sex-determining region of Y (SRY) and DYS14 as positive foetal controls.
J Perinatol
December 2024
Women and Children's Services, Providence Health and Services, Portland, OR, USA.
Maternal alloimmunization to paternal blood group antigens is the underlying cause of hemolytic disease of the fetus and newborn. Alloantibodies to the major, clinically significant blood group antigens are readily identified by the blood bank which, in turn, allows for appropriate monitoring of the maternal-fetal unit. However, uncommon blood group antibodies, particularly those directed against low and high prevalence antigens, present a more formidable challenge for obstetricians, neonatologists, and transfusion medicine specialists.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!